Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Xylene SCHEMBL1443687 | 0.81 | ACHE (0.61) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL18229935 | 0.80 | — | — | |
| P-Xylene SCHEMBL461064 | 0.80 | ACHE (0.89) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL28067071 | 0.80 | ACHE (0.89) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL10881674 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL28325850 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL10339754 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL10339755 | 0.79 | ALDH1A1 (0.58) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL10657290 | 0.76 | ACHE (0.80) | ALDH1A1CYP2A6ACHETDP1CA1 | |
| P-Xylene SCHEMBL11770184 | 0.76 | ACHE (1.00) | ALDH1A1CYP2A6ACHETDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118867392-A | Lithium ion battery electrolyte and application thereof | 东莞理工学院 | 2024-10-29 | — | — | CN | claimed |
| CN-118867392-A | Lithium ion battery electrolyte and application thereof | 东莞理工学院 | 2024-10-29 | — | — | CN | disclosed |
| CN-118867392-A | Lithium ion battery electrolyte and application thereof | 东莞理工学院 | 2024-10-29 | — | — | CN | disclosed |
| US-7855232-B2 | Organoselenium compound for cancer chemoprevention | LKT LABORATORIES, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20080108692-A1 | Organoselenium compound for cancer chemoprevention | LKT LABORATORIES, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-7314929-B2 | Alkylene selenocyanate or an alkylene isoselenocyanate moiety; anticancer agents | LKT LABORATORIES, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7087639-B2 | Organoselenium compounds for cancer chemoprevention | LKT LABORATORIES, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060079462-A1 | Organoselenium compounds for cancer chemoprevention | LKT LABORATORIES, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| US-20040158079-A1 | Organoselenium compounds for cancer chemoprevention | LKT LABORATORIES, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6703524-B2 | ANTICANCER AGENTS | LKT LABORATORIES, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020165215-A1 | Organoselenium compounds for cancer chemoprevention | LKT LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108692-A1 | Organoselenium compound for cancer chemoprevention | SELENOI, GPX1, BRCA1 | ALDH1A1 166/4885CYP2A6 761/4885ACHE 2333/4885 |
| US-20060079462-A1 | Organoselenium compounds for cancer chemoprevention | SELENOI, GPX1, BRCA1 | ALDH1A1 153/4885CYP2A6 745/4885ACHE 2318/4885 |
| US-20020165215-A1 | Organoselenium compounds for cancer chemoprevention | SELENOI, GPX1, BRCA1 | ALDH1A1 153/4885CYP2A6 745/4885ACHE 2318/4885 |
| US-20040158079-A1 | Organoselenium compounds for cancer chemoprevention | SELENOI, GPX1, BRCA1 | ALDH1A1 153/4885CYP2A6 745/4885ACHE 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.